🚨Acute #stroke case (from the archive):

Patient in 60s presents with sudden onset fluctuating LOC, dysarthria, mild right arm weakness (disabling)

Last seen normal 2hrs (witnessed onset).

You urgently take to CT- motion artifact, no clear early ischemic changes. CTA normal. Image
2 schools of thought/approaches:

Approach #1⃣: Acute onset, disabling symptoms- proceed with lytic 💉and defer CTP

Approach #2⃣: Dx is still a bit unclear (ddx: seizure⚡️, etc)- proceed to CTP

If in camp #2, here are the CTP maps (CBF, MTT, Tmax>8s) Image
CTP confirms suspected localization of left thalamus (with possible internal capsule involvement).

CTP helped confirm the etiology (not a mimic), but delayed lytic administration by about 7-10 min (did not change management).

Which camp/approach are you in for this case🧠?
FYI here is MRI done 2 days later.

#neurotwitter Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Andrew Micieli

Andrew Micieli Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MicieliA_MD

May 3, 2021
The tPA recommendation on the NNT website changed to "the net benefit & harms are unclear due to uncertainty of data" authored by @TheSGEM

I believe it's helpful to clarify a few points on this debate so we present families with correct info before they make a decision on tPA.
1. The main source for the recommendation is from a review paper in Emerg Med Australasia (see below).

This paper includes all thrombolytics (anistreplase, streptodornase, streptokinase, urokinase, lumbrokinase, duteplase, lanoteplase, pamiteplase, etc)

pubmed.ncbi.nlm.nih.gov/27561375/
Clumping the data to include all thrombolytics is not helpful, as only alteplase (tPA) is clinically used. We have moved on from the old thrombolytics.

When studying the new thrombolytic Tenecteplase in a RCT, we will not compare it to streptokinase. Thats not helpful.
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(